After a phase 3 study showed a promising pCR rate with HLX11, the pertuzumab biosimilar’s BLA has been accepted for review by the FDA.

FDA reviews biologics license application for HLX11, a biosimilar to pertuzumab, for HER2-positive breast cancer. The FDA accepted for review a biologics license application (BLA) seeking the approval ...

Q4 2024 Earnings Call Transcript February 26, 2025 Vir Biotechnology, Inc. beats earnings expectations. Reported EPS is ...

The breast cancer market has experienced robust growth, fueled by increased awareness and early detection efforts. Advances in diagnostic and treatment technologies have opened new avenues for ...

This study compared the carbon footprint of SC and IV administration using pertuzumab/trastuzumab as a case example. A Life Cycle Assessment was conducted to compare the environmental impacts of IV ...

For HER2-positive cancers, the guidelines advocate for dual-target therapies such as trastuzumab and pertuzumab, along with the introduction of pyrotinib in combination with trastuzumab as a novel ...

According to the National Comprehensive Cancer Network Breast Cancer Clinical Practice Guidelines, the standard-of-care first-line regimen for patients with HER2-positive recurrent/metastatic breast ...

and earlier this year launched a phase 3 study in previously untreated patients – DESTINY-Breast09 – which is comparing Enhertu with or without Roche's Perjeta (pertuzumab) to Perjeta ...

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines mark a significant milestone in breast cancer treatment, seamlessly ...

Darzalex & Darzalex Faspro are indicated for the treatment of multiple myeloma. Southeastern Grocer's president and CEO and C&S Wholesale Grocers have acquired Southeastern Grocers and its Winn ...